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ABSTRACT: Monomethyl auristatin E and monomethyl auristatin F are widely used cytotoxic
agents in antibody−drug conjugates (ADCs), a group of promising cancer drugs. The ADCs
speciﬁcally target cancer cells, releasing the auristatins inside, which results in the prevention of
mitosis. The auristatins suﬀer from a potentially serious ﬂaw, however. In solution, the molecules
exist in an equal mixture of two conformers, cis and trans. Only the trans-isomer is biologically
active and the isomerization process, i.e., the conversion of cis to trans is slow. This signiﬁcantly diminishes the eﬃciency of the
drugs and their corresponding ADCs, and perhaps more importantly, raises concerns over drug safety. The potency of the
auristatins would be enhanced by decreasing the amount of the biologically inactive isomer, either by stabilizing the trans-
isomer or destabilizing the cis-isomer. Here, we follow the computer-aided design strategy of shifting the conformational
equilibrium and employ high-level quantum chemical modeling to identify promising candidates for improved auristatins.
Coupled cluster calculations predict that a simple halogenation in the norephedrine/phenylalanine residues shifts the isomer
equilibrium almost completely toward the active trans-conformation, due to enhanced intramolecular interactions speciﬁc to the
active isomer.
KEYWORDS: cytotoxicity, molecular modeling, computer-aided drug design, intramolecular interactions, quantum chemistry,
drug development
■ INTRODUCTION
Monomethyl auristatin E (MMAE) and monomethyl auristatin
F (MMAF) are cell cytotoxic agents that bind to microtubules
and prevent cell proliferation by inhibiting mitosis.1−5 They are
used as warheads in a number of state-of-the-art antibody−
drug conjugates (ADCs).6−10 The eﬃciency of ADCs is based
on the highly selective targeting capabilities of the antibodies.
The antibody binds to certain proteins that the target, the
diseased cell, expresses more than the regular cells of the
body.6,11 Upon reaching their destination, i.e., the cancer cells
expressing the correct antigen, they are internalized by
endocytosis.6,12 Once inside the cell, the cytotoxic warhead
molecule, e.g., the auristatin, is released from the antibody,
causing cell death. Ideally, an ADC destroys the target cell
without causing harm to other cells, thus working like the
“magic bullets” envisioned by Paul Ehrlich at the beginning of
the 20th century.13−22
Like other cancer drugs that work by preventing cell
division, the side-eﬀects caused by the auristatins arise from
their eﬀects on the normal, quickly dividing cell-types of the
body. In fact, the auristatins are too toxic to be used as such
and are only used as part of ADCs in current treatments.
Common side-eﬀects of ADCs with the auristatin include
neutropenia, neuropathy, thrombocytopenia, and ocular
toxicities.23−25
The schematic structures of MMAE and MMAF are shown
in Figure 1. Both are composed of ﬁve amino acids. MMAE
consists of norephedrine, dolaproine, dolaisoleuine, valine, and
monomethyl valine. In MMAF, the C-terminal norephedrine is
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Figure 1.Molecular structures of MMAE (top) and MMAF (bottom)
in their cis conformations, and their constituent amino acids:
monomethyl valine (MeVal), valine (Val), dolaisoleuine (Dil),
dolaproine (Dap), and norephedrine (PPA)/phenylalanine (Phe).
The site of modiﬁcation considered here, R, is marked in green. The
blue arrow shows the peptide bond rotation leading to the trans-
isomer.
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replaced by phenylalanine. Recently, it was found that both
MMAE and MMAF exist as two diﬀerent conformational
isomers, denoted cis and trans with respect to the amide bond
between dolaproine and dolaisoleuine.22 In solution, the two
conformers have roughly equal proportions, but only one, the
trans-form, is biologically active.26
Now, to abate side-eﬀects, drug dosage should naturally be
kept at a minimum, while still reaching the desired potency. In
light of this, the fact that half of the auristatins delivered by
ADCs are ineﬀective is disquieting. Although it is true that the
inactive cis-conformer does isomerize to the active trans-form
by rotation around an amide bond, this process takes several
hours as the rotational energy barrier around the amide bond is
high (ca. 100 kJ/mol).22 Therefore, the auristatins may already
have escaped the conﬁnements of the targeted cancer cells
when they are transformed into active components, thus
potentially causing damage to healthy cells. This indication is
supported by recent studies on the hydrophobic nature of
auristatins.27
A good starting point for improving the properties of ADCs
would be to optimize the cytotoxic warheads currently in use.
In fact, modiﬁcation of auristatins has been an active ﬁeld of
study since the original modiﬁcations to dolastatin 10
itself,1,28,29 with various aspects of the drug molecules
tuned.27,30−37 Modifying the auristatins with the explicit goal
of decreasing the potential for side-eﬀects caused by the
presence of the dormant, biologically inactive cis-conformer is
a hitherto overlooked strategy, however. There are a couple of
alternatives for achieving this. If the barrier for conversion
between cis and trans could be lowered so much that the
interconversion would be signiﬁcantly faster, the drug
molecules would become active before leaving the diseased
cell. To decrease the time needed for conversion from hours
to, say, seconds, the rotational barrier would have to be
lowered by roughly 25 kJ/mol. This would, however, be
diﬃcult for the rather rigid peptide bond. Alternatively, the
rotational barrier could be further increased, practically locking
the conformation to either isomer. This might be possible with
suitable modiﬁcations to the structure, although rather bulky
ligands would probably be needed, aﬀecting also tubulin
binding.
An ideal modiﬁcation would instead of modifying the
barrier, shift the equilibrium from a 60:40 cis/trans distribution
toward the trans-conformer; then, the drug dosage as such
could be halved, and the problem of conversion between cis
and trans would be diminished. Here, using high-level
quantum mechanical modeling at the coupled-cluster CCSD-
(T) level, we investigate what kind of structural modiﬁcation
could aﬀord such a conformational equilibrium shift in the
auristatins, while at the same time maintaining a rather intact
binding aﬃnity to tubulin.
In general, accurately modeling ligand binding to large
biomolecules is a daunting task. In their comprehensive review
on the use of quantum chemical methods for estimating
binding aﬃnities, Ryde and Söderhjelm38 highlight the main
problem of quantum mechanical studies: the limitations on
conformational sampling imposed by the computational cost of
an otherwise accurate methodology. Although steps toward
solving the sampling problem are continuously taken, there is
still some way to go.39−46 From this perspective, the auristatins
are a rather agreeable object of study. Previously, by combining
NMR spectroscopy and quantum chemical modeling, we
showed that in solution, MMAE and MMAF exist as a mixture
of only two conformations; other structures are not present in
concentrations detectable by NMR.22 The same holds true for
other auristatin derivatives synthesized in the past.34 Thus, we
here have a case where high-accuracy modeling is viable also in
molecular pharmaceutics, due to the limited conformational
space of the drug molecules.
Below, we show that an almost complete shift toward the
trans-isomer can be achieved by a minimal change to the
molecular structure: halogenation of the norephedrine and
phenylalanine residues in MMAE and MMAF, respectively.
■ METHODS
The geometries were optimized at density functional theory
(DFT) level,47 using the hybrid Tao−Perdew−Staroverov−
Scuseria functional corrected for dispersion interactions,
TPSSh-D3(BJ),48−51 with the def2-TZVPP (for isomer energy
diﬀerences) and def2-SVP (for vibrational frequencies and the
tubulin−MMAE complex) basis sets.52 Solvation eﬀects were
accounted for with the COSMO model.53 Final electronic
energies were computed at the domain-based local pair natural
orbital DLPNO-CCSD(T) coupled cluster level of
theory,54−56 extrapolating toward the complete basis set limit
using the two-point formula by Halkier et al.57 in connection
with the def2-TZVPPD and def2-QZVPPD triple- and
quadruple-ζ basis set augmented with diﬀuse functions.52,58
Enthalpies and free energies were estimated from the harmonic
vibrational frequencies, with possible low-frequency modes
below 50 cm−1 set to 50 cm−1, using gas-phase structures and
frequencies. For the tubulin models, the contributions from the
ﬁxed atoms were discarded. We note the good agreement
between simulation and experiment for the original MMAE
and MMAF (see Table 3), corroborating the suitability of the
present level of theory, as reported also in previous
studies.59−61 Intramolecular, noncovalent interaction (NCI)
energies were computed using F/I-SAPT0,62−64 in connection
with the Pauling point65 providing the jun-cc-pVDZ basis
set,66 without implicit solvent. For the symmetry-adapted
perturbation theory (SAPT) analysis, the fragments were
divided after the peptide bond (counting from the C-terminus)
to perform the cut at a single σ-bond, instead of cutting the
actual OC−NH bond. The tubulin−MMAE interactions at the
DFT level were computed with the def2-TZVPP basis set,
using counter-poise correction.67 Ligand docking was
performed with AutoDock version 4.2.6,68,69 with the
calculations set up with AutoDockTools version 1.5.6. The
crystal structure of the tubulin−MMAE complex (PDB ID
5IYZ)26 was used as a template. As the binding site is at the
interface of chains B and C, other chains, water, and the
original ligand (ID 4Q5) were deleted before docking. For the
protein, standard Gasteiger charges70 were used, while for the
ligands, restrained electrostatic potential (RESP) charges71
were computed, based on the TPSSh/def2-TZVPP electron
density. All ligand torsion angles, except for the four bonds in
the norephedrine moiety, were set to nonrotatable (inactive).
A grid box of 40 × 60 × 40 points centered at the original
ligand position was calculated with AutoGrid, using default
values for other settings. For all ligands, a total of 500
independent search runs utilizing the Lamarckian genetic
algorithm,72 each with a maximum of 2.5 million energy
evaluations, were performed; the lowest energy docking pose
was in all cases located after 20 search runs.
The DFT calculations were performed with TURBOMOLE
versions 7.2 and 7.3,73−75 the RESP calculations with
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NWChem version 6.8,76 the coupled cluster calculations with
Orca version 4.0.1.2,77 the SAPT calculations with PSI4
version 1.1,78 and the noncovalent interaction analysis with
NCIplot version 3.79 Default recommended settings and
thresholds were used with the following exceptions: the DFT
calculations used the ﬁne m4 grid, except for the vibrational
frequencies where the super-ﬁne m5 grid was employed; the
coupled cluster calculations were performed with the
TightPNO setting. Jmol80 and VMD81 were used for
visualization.
■ RESULTS
Shifting the cis/trans Equilibrium. To alter the relative
stability of the isomers in solution by structural modiﬁcation,
two main strategies can be employed: (1) modifying the
structure so that the interactions between the molecule and the
environment, e.g., the solvent, favor one isomer over the other;
or (2) modifying the structure so that the intramolecular
interactions within the molecule favor one isomer over the
other. The nature of the structure modiﬁcation can be further
divided into two, based on if it: (a) stabilizes the active trans-
isomer; or (b) destabilizes the inactive cis-isomer.
Naturally, the classes are not mutually exclusive. Any
structural modiﬁcation will exhibit changes in both inter- and
intramolecular interactions, and aﬀect both isomers, to some
degree.
Modifying the interactions between a drug molecule and its
environment will not only aﬀect solute−solvent interactions
but will also modify interactions with the drug target. This
might be either beneﬁcial or disadvantageous. Tweaking the
internal interactions of a molecule will have a lesser eﬀect on
the interactions with the binding site. In the present case,
where the drug as such works well when in its active
conformation, we opt for the strategy of modifying the
intramolecular interactions of MMAE and MMAF so that they
favor the active trans-conformation over cis.
We recently conducted a combined NMR-spectroscopic and
molecular modeling study on the solution properties of MMAE
and MMAF.22 Looking at the three-dimensional structures of
the cis and trans-conformers, see Figure 2, one can note some
obvious diﬀerences between the two conformers. The trans-
conformers form an extended structure which corresponds to
the tubulin-bound form of the molecule, while the cis-
conformers form a more contorted, compact structure that
does not ﬁt into the receptor pocket.22,26,82 Our strategy-of-
choice is to shift the conformer equilibrium in favor of the
trans-conformers. This implies introducing structural mod-
iﬁcations that stabilize the trans-isomer, destabilize the cis-
isomer, or a combination of both.
To properly dissect the interactions between the phenyl
group and the rest of the molecule, we performed an analysis
using symmetry-adapted perturbation theory for functional
groups and intramolecular interactions, F/I-SAPT0.62−64
Tables 1 and 2 show the interactions for MMAE and
MMAF, respectively.
The interactions within MMAE and MMAF are nearly twin.
Comparing the cis and trans-isomers, we see that the
intramolecular interactions between the phenyl and the rest
of the molecule are somewhat more favorable in the cis-form.
The majority of the total interaction energy comes from
interactions between the phenyl (Ph) and the dolaproine
(Dap). A closer look at the individual interactions shows,
however, that in the cis-form, the interactions between Ph and
the dolaisoleuine (Dil) are signiﬁcant as well, but attractive
electrostatic and dispersion interactions are almost completely
canceled by the steric repulsion manifested in the exchange
interaction. In both isomers, the interactions between Ph and
the two valines at the opposite end of the chain are weak.
Induction interactions are rather weak overall as well.
Modiﬁcation of the phenyl ring thus has the potential to
tune the intramolecular interactions signiﬁcantly, and im-
Figure 2. cis and trans-isomers of MMAE. The colors mark the
grouping used in the intramolecular energy analysis: Ph (gray), link
atoms (yellow), Dap (red), Dil (light blue), Val (purple), and MeVal
(green). The site of modiﬁcation, R, is marked by a green sphere; the
blue arrow shows the peptide bond rotation leading to the trans-
isomer, and the peptide bond itself is marked by a thick, dashed, green
bond.
Table 1. Intramolecular Interaction Energies (kJ/mol)
between the Terminal Phenyl Group (Ph) and the Four
Remaining Amino Acids in the cis and trans-Isomers of
MMAE, Grouped by the Type of Interaction
electrostatic exchange induction dispersion total
cis
Ph−Dap −14.0 +19.9 −5.1 −23.4 −22.6
Ph−Dil −6.3 +26.9 −2.8 −19.8 −2.0
Ph−Val −3.0 +1.4 +0.1 −3.7 −5.3
Ph−MeVal +0.3 +0.0 −0.1 −0.1 +0.1
Ph−All −23.0 +48.2 −7.9 −47.1 −29.8
trans
Ph−Dap −13.2 +37.9 −6.9 −35.2 −17.3
Ph−Dil −2.9 +0.4 +0.5 −3.3 −5.2
Ph−Val +0.2 +0.0 +0.1 −0.1 +0.2
Ph−MeVal −0.1 +0.0 +0.0 −0.0 −0.1
Ph−All −16.0 +38.4 −6.2 −38.6 −22.4
Table 2. Intramolecular Interaction Energies (kJ/mol)
between the Terminal Phenyl Group (Ph) and the Four
Remaining Amino Acids in the cis and trans-Isomers of
MMAF, Grouped by the Type of Interaction
electrostatic exchange induction dispersion total
cis
Ph−Dap −13.8 +18.0 −4.6 −21.4 −21.8
Ph−Dil −5.3 +25.2 −3.2 −20.1 −3.3
Ph−Val −3.5 +2.7 +0.1 −4.8 −5.5
Ph−MeVal +0.2 +0.0 −0.1 −0.1 −0.0
Ph−All −22.4 +45.9 −7.7 −46.4 −30.6
trans
Ph−Dap −11.1 +34.6 −6.4 −33.5 −16.5
Ph−Dil −3.0 +0.4 +0.5 −3.1 −5.2
Ph−Val +0.1 +0.0 +0.1 −0.1 +0.2
Ph−MeVal −0.1 +0.0 +0.0 −0.0 −0.1
Ph−All −14.1 +35.0 −5.8 −36.7 −21.6
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portantly, in a diﬀerent manner for the two isomers. To
minimize the changes in extramolecular interactions, the
modiﬁcation should in general be small, by some measure.
Halogenation is a well-established strategy in drug develop-
ment, and a signiﬁcant portion of the drugs on the market
contain ﬂuorine and/or chlorine.83−86 Furthermore, halogen-
ation should have an immediate eﬀect on all of the important
intramolecular interactions. A priori, one could expect
dispersion interactions to become stronger, especially for
chlorinated species. This eﬀect could be oﬀset by a possible
increase in steric exchange repulsion due to the larger size of
the halogens, at least if the geometry otherwise stays constant.
Providing an educated guess for the change in electrostatic
interactions arising from the substitutions is more diﬃcult, as
there will be a signiﬁcant redistribution of charge due to the
electron-withdrawing halogens. Fortunately, all of the induced
changes can be tracked with the F/I-SAPT0 method, rendering
guesswork a stimulating but superﬂuous activity.
Here, we opt for substituting one of the ﬁve hydrogens of
the terminal phenyl group by either ﬂuorine or chlorine.
Exploratory modeling at the DFT level found methyl
substitution to be inferior to halogenation, and that
substitution at the meta position favors the cis-isomer, see
Table S1 in the Supporting Information. Furthermore, while
the rotation around the phenyl C−C bond is reasonably fast in
solution, this might not be the case when bound to tubulin.
Thus, substitution at the meta and ortho positions would
double the number of isomers to be considered, exacerbating
the conformer issue. Another aspect favoring substitutions in
the para-position is that it represents a feasible synthetic route
for modiﬁcation.
Table 3 shows the energy diﬀerence between the cis and
trans forms of MMAE, MMAF, and their halogenated
analogues, computed at the CCSD(T) level, in a simulated
water medium at 37 °C (see Methods for details), as well as
the available experimental data;22 we note that computing the
thermal corrections at 295 and 310 K results in the same
simulated relative energies for MMAE and MMAF.
As a side note, a comparison to the relative energies
computed at the DFT level (Table S1) underlines the
importance of using a highly accurate level of theory for
computing the isomer distribution. For both MMAE and
MMAF, the DFT calculations unduly favor the cis-isomer by 6
kJ/mol, thus predicting cis/trans-isomer ratios of 94:6 and
91:9 for MMAE and MMAF, respectively.
Chlorination of MMAE has a rather small eﬀect on the cis/
trans ratio. The three other halogenations shift the equilibrium
signiﬁcantly toward the preferred trans-isomer. The most
promising results are seen for chlorinated MMAF, where the
computed cis/trans ratio is 6:94. Compared to pure MMAF,
the amount of problematic cis-isomer is thus reduced to a
tenth.
Table 4 shows a summary of the F/I-SAPT0 analysis of the
changes in intramolecular interactions between the terminal
phenyl group and the Dap and Dil residues upon halogenation
for MMAE and MMAF.
From the data in Table 4, one can note a common feature:
halogenation always decreases the intramolecular attraction
within the cis-isomers, while the interactions within the trans-
isomer become more favorable. This is the main driving force
for the shift toward the trans-isomer upon halogenation at the
para-position of the phenyl group in both MMAE and MMAF.
The individual components of the interaction energies also
show some common features. In all cis-isomers, the electro-
static attraction is decreased (but stays attractive), while the
trans-isomers experience an enhanced electrostatic attraction.
For the steric exchange repulsion, the situation is reversed,
with the halogenated cis-forms consistently having less steric
repulsion than their unsubstituted counterparts, despite the
larger size of the halogens compared to hydrogen.
For the chlorinated species, dispersion interactions are, as
expected, enhanced. This is also clearly evident in the
noncovalent interaction (NCI) analysis. NCI analysis reveals
regions in the molecule where weak interactions like dispersion
are manifested, based on various properties of the electron
density,79,87 and is known to work well for halogenated
species.88 Figure 3 shows the NCIplot in real-space for MMAE
and Cl-MMAE; the expansion of the region of dispersion
interactions is rather notable, now extending further from the
phenyl−pyrrolidine stacking interaction.
For the ﬂuorinated species, changes in the dispersion
interactions are damped compared to their chlorinated
counterparts, and in the case of the cis-isomer, dispersion
actually decreases. Thus, while the general trends of the
changes perhaps could be predicted a priori, the relative
magnitudes, and sometimes even the direction of the
adjustment require rigorous quantum chemical studies.
Interaction with Tubulin. In the previous section, we
identiﬁed two, maybe three promising candidates for improved
auristatins, based on the criterion that the biologically active
trans-isomer should be dominant. In decreasing order of
potency, these are the para-substituted Cl-MMAF, F-MMAF,
and F-MMAE, with predicted portions of 94, 90, and 79%
trans-isomer in solution, respectively, compared to the 38 and
52% of the original, unsubstituted MMAE and MMAF. A more
favorable cis/trans ratio is in itself not enough, however. The
new molecules have to perform well also in their therapeutic
function of binding to the tubulins.
Although halogenation was chosen as a minimally intrusive
chemical modiﬁcation from the extramolecular standpoint,
some changes in the interactions with the environment are
always to be expected. The simulated changes in solvation free
energy are +1.9, +1.4, and +1.4 kJ/mol for the trans-
conformations of Cl-MMAF, F-MMAF, and F-MMAE,
respectively, that is, slightly less soluble in water. Changing
the dielectric constant from 78 to 32.6, simulating methanol, or
alternatively, the lower dielectricity inside cells,89,90 changes
the relative solvation energies by at most 0.1 kJ/mol. Overall,
Table 3. Energy Diﬀerences (kJ/mol) between the cis and
trans-Isomers of the Studied Auristatinsa
cis−trans energy diﬀerence (cis/trans ratio)
molecule ΔH, 310 K ΔG, 310 K ΔG, 295 K, exp
MMAE +1.0 (59:41) +1.3 (62:38) +0.9 (59:41)
para-F-MMAE −4.0 (17:83) −3.4 (21:79)
para-Cl-MMAE −1.2 (39:61) −0.3 (47:53)
MMAF −0.1 (49:51) −0.2 (48:52) +0.5 (55:45)
para-F-MMAF −7.0 (6:94) −5.6 (10:90)
para-Cl-MMAF −7.4 (5:95) −7.2 (6:94)
aThe energies of the cis-isomers are set to zero, so a negative value
indicates that the speciﬁc trans-isomer is lower in energy (Boltzmann
ratios within parentheses). Computed at the DLPNO-CCSD(T)/
def2-[T,Q]ZVPPD/COSMO level.
Molecular Pharmaceutics Article
DOI: 10.1021/acs.molpharmaceut.9b00437
Mol. Pharmaceutics 2019, 16, 3600−3608
3603
the solvation energy diﬀerences are very small, indicating small
changes also in the interaction with other molecules and
moieties like the tubulin binding pocket.
To more directly estimate the binding energy for the
modiﬁed auristatins, we constructed a model of the binding
pocket, using the crystal structure PDB ID 5IYZ26 as a starting
point. The model includes the MMAE ligand and the residues
within 5 Å from the para-hydrogen of the C-terminal phenyl,
that is, Gln-11, Gln-15, Lys-19, Tyr-224, Gly-225, Asn-228,
and the guanosine diphosphate 501, as well as 8 of the closest
crystal waters, in total 293 atoms, see Figure 4. The model thus
includes the most important residues that would experience
and exert modiﬁed interactions with the ligand due to
halogenation. The structural diﬀerence between MMAE and
MMAF, that is, the diﬀerence between norephedrine and
phenylalanine, lies ﬁve bonds away from the site of
modiﬁcation. Therefore, the assumption that the change in
interaction energies upon halogenation will be very similar for
MMAE and MMAF should be a good ﬁrst approximation, even
if distant ligand substitutions can have a non-negligible eﬀect
on intermolecular interactions.91 Ideally, an even larger model
of the binding site, where also residues surrounding the −OH/
−COOH groups of MMAE/MMAF are included would be
employed; this would lead to an inordinate model system size,
however.
Table 4. Interaction Energy Diﬀerences (kJ/mol) between Halogenated and Unsubstituted MMAE and MMAFa
MMAE MMAF
halogen, isomer elst. exch. disp. total elst. exch. disp. total
F, cis
Ph−Dap +8.3 −3.7 +1.9 +7.6 +7.8 −1.4 +0.7 +7.5
Ph−Dil +2.7 −5.2 +2.0 +0.1 +0.9 +0.5 −0.6 +0.9
Ph−All +10.3 −9.6 +4.6 +6.9 +7.6 −1.3 +0.2 +7.0
F, trans
Ph−Dap −5.7 +1.7 −1.5 −5.3 −5.7 +2.0 −1.9 −5.4
Ph−Dil +0.7 +0.9 −1.0 +0.2 +0.6 +1.0 −1.2 +0.0
Ph−All −4.9 +2.6 −2.6 −4.9 −5.0 +3.0 −3.1 −5.3
Cl, cis
Ph−Dap +7.5 +0.7 −4.2 +4.0 +7.1 +1.8 −5.2 +3.6
Ph−Dil +0.9 −0.8 −1.3 −1.1 +0.1 −0.5 −0.8 −0.7
Ph−All +7.7 −0.9 −5.0 +2.0 +6.8 −0.4 −4.8 +1.9
Cl, trans
Ph−Dap −5.4 −1.1 −3.7 −10.2 −5.8 −0.4 −4.2 −10.5
Ph−Dil −0.6 +6.3 −4.9 +0.4 −0.4 +5.9 −4.7 +0.4
Ph−All −5.8 +5.3 −8.7 −9.6 −5.9 +5.4 −8.9 −9.9
aNegative values indicate that the halogenation lowers the energy. The “total” interaction energies include induction terms and the “Ph−All” terms
include contributions from the valines.
Figure 3. Plot of noncovalent interactions in the trans-conformations of MMAE (left) and Cl-MMAE (right). Green areas depict dispersion
interactions within the molecules.
Figure 4. Model of MMAE bound to tubulin. The structures of
MMAE and the water molecules are shown as stick models, and the
closest amino acids and the guanosine diphosphate are shown as
colored space-ﬁlling spheres.
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At the F/I-SAPT0 level, the interaction energy diﬀerences
are comparable to the diﬀerences in solvation energy, with the
F-MMAE and Cl-MMAE interaction energies decreased by 0.3
and 2.0 kJ/mol, respectively.
Dispersion-corrected DFT interaction energies corroborate
these ﬁndings: at the TPSSh-D3 level, F-MMAE and Cl-
MMAE interactions with the tubulin model are weaker by 0.6
and 1.7 kJ/mol respectively, compared to the unmodiﬁed
MMAE. Looking at total binding energies from the model, that
is, using relaxed MMAE structures, the binding is slightly less
favorable for the halogenated species, with binding free energy
weaker by 4.1 and 4.4 kJ/mol for F-MMAE and Cl-MMAE,
respectively. This can be traced to the interference of the
tyrosine residue (Tyr-224, see Figure 4) which functions as a
wedge, separating the terminal phenyl from the pyrrolidine.
The increase in the stability of the halogenated trans-isomers
that springs from the increased favorable intramolecular
interactions are thus dampened upon tubulin binding. Thus,
while the actual binding strength, measured as the direct
interaction energy between the ligand and the binding site, is
almost unaﬀected, the computed binding free energy is
somewhat weaker.
We duly note that the molecular model used for computing
the drug−tubulin interaction will have a non-negligible eﬀect
on the binding energy. Here, we chose a model as large as
possible, considering computing capability. To keep the
tubulin frame of the model in close correspondence to the
experimental structure, some surface atoms require ﬁxing to
their crystallographic positions; also, the positions of the H2O
oxygens were ﬁxed to restrict their movement away from the
binding site. As the positions of the amino acids in the binding
pocket have been constrained based on the crystal structure of
the unsubstituted MMAE/tubulin complex, there might be a
slight bias against the halogenated species, as the halogens
naturally are somewhat larger than the hydrogen they replace.
We also performed a simulated molecular docking study of
MMAE, F-MMAE, and Cl-MMAE to tubulin, using the
AutoDock protocol (see Methods). Docking models naturally
have their own limitations,92 but do provide a complementary
view on the binding aﬃnity. The experimental docking pose26
was located as the minimum for MMAE, and the halogenated
derivatives were docked in a near-identical manner. The
minimum energy docking position for both F-MMAE and Cl-
MMAE was found to bind minutely weaker, by 1.1 kJ/mol.
The predicted mean binding energy was also slightly lower, by
1.5 and 1.8 kJ/mol for F-MMAE and Cl-MMAE, respectively.
Also here, a slight bias toward the original MMAE is possible,
as the binding pocket was ﬁxed to the crystal structure.
The binding aﬃnity of a drug molecule is of course very
sensitive to the interaction energy between the drug and its
target. Using the simple ΔG = −RT ln(Kd) relation, a ΔΔG of
6 kJ/mol changes the binding aﬃnity by an order of
magnitude. At a minimum, the simple exploration presented
in this section gives no reason for concern regarding the
binding of the modiﬁed drugs. This is especially true for the
halogenated MMAF derivatives, as MMAF in itself is known to
bind 5 times stronger to the tubulins compared to MMAE.26
■ CONCLUSIONS
The cytotoxic auristatins are widely used warheads in modern
ADCs. They do, however, suﬀer from a potentially serious
ﬂaw: in solution, half of the drug molecules exist, temporarily,
in their biologically inactive cis-conformation. This raises a
number of concerns regarding their safety and eﬃcacy. The
active trans-isomer will, after its release in the cancer cell,
quickly bind to tubulin, causing apoptosis, while the cis-form
remains inactive. The cis-isomer will, eventually, also activate
by transforming into the trans-form; this activation might,
however, come too late, when the drug molecule has already
escaped the conﬁnes of the target cell into healthy tissue.
The existence of two distinct isomers also suggests an
immediate route for developing improved derivatives. Herein,
we have focused on the rational design of novel auristatin
derivatives which would favor the biologically active trans-
conformation. By performing a careful quantum chemical
investigation of the intramolecular forces governing the cis/
trans equilibrium, we have identiﬁed candidates for improved
cancer therapeutics. High-level coupled cluster calculations
suggest that a halogen substitution at the para-position of the
C-terminal phenyl ring in MMAE and MMAF leads to
signiﬁcantly more favorable isomer ratios. The most promising
candidates are the chlorinated and ﬂuorinated MMAF
derivatives, which are predicted to shift the trans ratio to 94
and 90%, respectively. In terms of ADC research, this suggests
that with these improved warheads the administrated doses
could be reduced by 40−50% without aﬀecting the eﬃcacy of
the ADCs. A decrease in the required drug dosage is in itself
advantageous. From another point of view, the amount of
potentially harmful cis-isomer administered is reduced
signiﬁcantly.
Presently, it is naturally impossible to ascertain whether
these simple halogenated derivatives will proceed all the way
through clinical trials, or if the candidates will require
additional tuning of their properties. Nevertheless, we have
shown that the amount of the temporarily inactive cis-form of
the auristatins can be addressed already at the computational
drug design stage. Furthermore, the modiﬁcations have been
designed with synthetic feasibility and tubulin binding
interactions in mind.
In general, tuning the conformational equilibrium oﬀers a
new, complementary avenue for reaching improved auristatin-
based cancer pharmaceuticals to those currently pursued in the
scientiﬁc literature.
■ ASSOCIATED CONTENT
*S Supporting Information
The Supporting Information is available free of charge on the
ACS Publications website at DOI: 10.1021/acs.molpharma-
ceut.9b00437.
Isomer energy diﬀerences computed at the DFT level;
atomic coordinates of modiﬁed auristatins and auri-
statin/tubulin models; deﬁnition of ﬁxed atoms;
AutoDock PDBQT ligand ﬁles (PDF)
■ AUTHOR INFORMATION
Corresponding Author
*E-mail: mikael.johansson@helsinki.ﬁ.
ORCID
Iris K. Sokka: 0000-0002-5148-4987
Filip S. Ekholm: 0000-0002-4461-2215
Mikael P. Johansson: 0000-0002-9793-8235
Notes
The authors declare no competing ﬁnancial interest.
Molecular Pharmaceutics Article
DOI: 10.1021/acs.molpharmaceut.9b00437
Mol. Pharmaceutics 2019, 16, 3600−3608
3605
■ ACKNOWLEDGMENTS
CSC-The Finnish IT Center for Science and the Finnish Grid
and Cloud Infrastructure (urn:nbn:ﬁ:research-infras-
2016072533) provided ample computer time. This work has
been supported by the Academy of Finland (projects 289179
and 319453), Jane and Aatos Erkko Foundation, Waldemar
von Frenckells stiftelse, and University of Helsinki research
funds.
■ REFERENCES
(1) Bai, R.; Pettit, G. R.; Hamel, E. Dolastatin 10, a Powerful
Cytostatic Peptide Derived from a Marine Animal. Biochem.
Pharmacol. 1990, 39, 1941−1949.
(2) Wu, A. M.; Senter, P. D. Arming Antibodies: Prospects and
Challenges for Immunoconjugates. Nat. Biotechnol. 2005, 23, 1137−
1146.
(3) Doronina, S. O.; Mendelsohn, B. A.; Bovee, T. D.; Cerveny, C.
G.; Alley, S. C.; Meyer, D. L.; Oflazoglu, E.; Toki, B. E.; Sanderson, R.
J.; Zabinski, R. F.; et al. Enhanced Activity of Monomethylauristatin F
through Monoclonal Antibody Delivery: Effects of Linker Technology
on Efficacy and Toxicity. Bioconjugate Chem. 2006, 17, 114−124.
(4) Senter, P. D.; Sievers, E. L. The Discovery and Development of
Brentuximab Vedotin for Use in Relapsed Hodgkin Lymphoma and
Systemic Anaplastic Large Cell Lymphoma. Nat. Biotechnol. 2012, 30,
631−637.
(5) Chen, H.; Lin, Z.; Arnst, K.; Miller, D.; Li, W. Tubulin Inhibitor-
Based Antibody-Drug Conjugates for Cancer Therapy. Molecules
2017, 22, No. 1281.
(6) Schrama, D.; Reisfeld, R. A.; Becker, J. C. Antibody Targeted
Drugs as Cancer Therapeutics. Nat. Rev. Drug Discovery 2006, 5,
147−159.
(7) Mullard, A. Maturing Antibody−Drug Conjugate Pipeline Hits
30. Nat. Rev. Drug Discovery 2013, 12, 329−332.
(8) Diamantis, N.; Banerji, U. Antibody-Drug Conjugatesan
Emerging Class of Cancer Treatment. Br. J. Cancer 2016, 114, 362−
367.
(9) Lucas, A.; Price, L.; Schorzman, A.; Storrie, M.; Piscitelli, J.;
Razo, J.; Zamboni, W. Factors Affecting the Pharmacology of
Antibody−Drug Conjugates. Antibodies 2018, 7, 10.
(10) Lu, Z.-R.; Qiao, P. Drug Delivery in Cancer Therapy, Quo
Vadis? Mol. Pharmceutics 2018, 15, 3603−3616.
(11) Alberts, B.; Johnson, A. D.; Lewis, J.; Morgan, D.; Raﬀ, M.;
Roberts, K.; Walter, P. Molecular Biology of the Cell, 6th ed.; Garland
Science, Taylor & Francis Group: New York, NY, 2015.
(12) Kovtun, Y. V.; Goldmacher, V. S. Cell Killing by Antibody−
Drug Conjugates. Cancer Lett. 2007, 255, 232−240.
(13) Ehrlich, P. Experimental Researches on Speciﬁc Therapy: On
Immunity with Special Reference to the Relationship between
Distribution and Action of Antigens. First Harben Lecture (1907).
In The Collected Papers of Paul Ehrlich; Elsevier, 1960; pp 106−117.
(14) Ehrlich, P. Address in Pathology, ON CHEMIOTHERAPY:
Delivered before the Seventeenth International Congress of Medicine.
Br. Med. J. 1913, 2, 353−359.
(15) Albert, A. Selective Toxicity. Nature 1950, 165, 12−16.
(16) Schwartz, R. S. Paul Ehrlich’s Magic Bullets. N. Engl. J. Med.
2004, 350, 1079−1080.
(17) Winau, F.; Westphal, O.; Winau, R. Paul Ehrlich  in Search
of the Magic Bullet. Microbes Infect. 2004, 6, 786−789.
(18) Lewis, L. D. Cancer Pharmacotherapy: 21st Century “magic
Bullets” and Changing Paradigms. Br. J. Clin. Pharmacol. 2006, 62, 1−
4.
(19) Bosch, F.; Rosich, L. The Contributions of Paul Ehrlich to
Pharmacology: A Tribute on the Occasion of the Centenary of His
Nobel Prize. Pharmacology 2008, 82, 171−179.
(20) Strebhardt, K.; Ullrich, A. Paul Ehrlich’s Magic Bullet Concept:
100 Years of Progress. Nat. Rev. Cancer 2008, 8, 473−480.
(21) Lambert, J. M. Antibody−Drug Conjugates (ADCs): Magic
Bullets at Last! Mol. Pharmceutics 2015, 12, 1701−1702.
(22) Johansson, M. P.; Maaheimo, H.; Ekholm, F. S. New Insight on
the Structural Features of the Cytotoxic Auristatins MMAE and
MMAF Revealed by Combined NMR Spectroscopy and Quantum
Chemical Modelling. Sci. Rep. 2017, 7, No. 15920.
(23) Okeley, N. M.; Miyamoto, J. B.; Zhang, X.; Sanderson, R. J.;
Benjamin, D. R.; Sievers, E. L.; Senter, P. D.; Alley, S. C. Intracellular
Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug
Conjugate. Clin. Cancer Res. 2010, 16, 888−897.
(24) Donaghy, H. Effects of Antibody, Drug and Linker on the
Preclinical and Clinical Toxicities of Antibody-Drug Conjugates.
mAbs 2016, 8, 659−671.
(25) Lambert, J. M.; Morris, C. Q. Antibody−Drug Conjugates
(ADCs) for Personalized Treatment of Solid Tumors: A Review. Adv.
Ther. 2017, 34, 1015−1035.
(26) Waight, A. B.; Bargsten, K.; Doronina, S.; Steinmetz, M. O.;
Sussman, D.; Prota, A. E. Structural Basis of Microtubule
Destabilization by Potent Auristatin Anti-Mitotics. PLoS ONE 2016,
11, No. e0160890.
(27) Ekholm, F.; Ruokonen, S.-K.; Redoń, M.; Pitkan̈en, V.;
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